Rapport Therapeutics Inc (RAPP) Stock Price, Quote & News

Company Profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including periphe...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 321 8020

Website: www.rapportrx.com

Address:

1325 Boylston Street, Suite 401, Boston, United States

Doozio Aug. 19 at 12:56 AM

Out of 🐑⏰♾️ it’s a $RAPP wen they $ALLY $LE oop on 🐑 during as 🐒🍌🧠⏰♾️ gets its $SWAG

0 · Reply

Doozio Aug. 17 at 10:35 PM

Out of 🐑⏰♾️ it’s a $RAPP with Roger rocking this new Baker Bros pos during 🐒🍌🧠⏰♾️

0 · Reply

perchedcats Aug. 9 at 3:11 PM

$RAPP few follow this… catalyst coming up… i am staying on sidelines feel valuation is a bit high already will wait until readout

0 · Reply

d_risk Aug. 7 at 2:26 PM

$RAPP - Rapport Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors RAPP’s 10-Q risk factors reveal major expansions in regulatory, clinical, IP, cybersecurity, AI/ML, and partnership risks; new dilution and capital raise concerns; heightened geopolitical, tax, and litigation exposures; plus emerging growth company status and controls limitations—all signaling increased operational and financial complexity. #Biotechnology #GrowthCompany #LitigationRisk #GeopoliticalRisk #CapitalRaising #ArtificialIntelligence #Cybersecurity #IntellectualProperty #ClinicalTrials #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/RAPP/10-Q/2025-08-07

0 · Reply

JarvisFlow Aug. 6 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Rapport Therapeutics ( $RAPP ), setting the rating to Buy with a target price of 31.

0 · Reply

UCF_16 Jul. 24 at 11:36 PM

$FIX $RAPP $SCHL $WLGS Lets go $WLGS - to the moon 🌗 🎆🚀🔥

0 · Reply

Whiskey1679 Jul. 24 at 11:35 PM

Whiskeya Picks out tomorrow approx. 6:20 am PDT! Trending: $SCHL $FIX $RAPP $WLGS $BMIX

0 · Reply

Quantumup Jul. 18 at 12:46 PM

H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine, for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG NBIX ( LBPH - HLBBF HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures, there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed vormatrigine's potential in FOS—we make that statement despite being "bulls" on the vormatrigine story. We believe the efficacy that relutrigine demonstrated in the EMBOLD study was potentially paradigm-shifting in its ability to offer seizure freedom to patients. H.C. Wainwright went on to say:

1 · Reply

Quantumup Jul. 16 at 10:02 AM

Citizens reiterated $RAPP Market Outperform-$28 after a KOL call reinforced its confidence in the pot'l for positive RAP-219 Phase 2 results in focal epilepsy. $PRAX $XENE $BHVN $NBIX TAK UCBJY Citizens said in its note: "We recently hosted Dr. Vikram Rao, a neurologist from UCSF and epilepsy KOL, for a discussion on the upcoming Phase 2 proof-of-concept results for RAP-219 in focal epilepsy. Dr. Rao is optimistic about the potential for RAP-219 in focal epilepsy due to its validated yet differentiated mechanism of action, compelling preclinical results, and innovative Phase 2 trial design. RAPP remains one of our two high-conviction calls into the Phase 2 results in September."

0 · Reply

oneyedjacks Jul. 10 at 8:04 PM

$RAPP Garbage

0 · Reply

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

Jun 2, 2025, 2:45 PM EDT - 2 months ago

Rapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate Updates

May 27, 2025, 7:00 AM EDT - 3 months ago

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 3 months ago

Rapport Therapeutics to Host 2025 Investor and Analyst Day

May 8, 2025, 7:00 AM EDT - 3 months ago

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Apr 30, 2025, 11:45 AM EDT - 4 months ago

Mise à disposition du rapport financier annuel 2024

Apr 22, 2025, 7:00 AM EDT - 4 months ago

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Apr 18, 2025, 7:46 AM EDT - 4 months ago

Meloni and Trump: An Oval Office Meeting With Rapport and Banter

Mar 27, 2025, 7:00 AM EDT - 5 months ago

Crédit Agricole Ille-et-Vilaine : Communiqué de mise à disposition du rapport financier 2024

Mar 21, 2025, 2:26 PM EDT - 5 months ago

Bpce: Mise à disposition du document d'enregistrement universel 2024 et du rapport financier annuel du Groupe BPCE

Mar 21, 2025, 7:00 AM EDT - 5 months ago

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Mar 13, 2025, 12:14 PM EDT - 5 months ago

Correction: Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 13, 2025, 3:00 AM EDT - 5 months ago

Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024

Mar 11, 2025, 7:00 AM EDT - 5 months ago

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 7:00 AM EST - 6 months ago

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Jan 9, 2025, 9:12 AM EST - 7 months ago

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Jan 9, 2025, 7:00 AM EST - 7 months ago

Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Dec 6, 2024, 12:01 PM EST - 9 months ago

Rapport Therapeutics Presents Data Demonstrating Consistent Association Between Decreases in RNS Measured Long Episodes and Meaningful Reductions in Clinical Seizures

Nov 14, 2024, 7:00 AM EST - 9 months ago

Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting

Nov 4, 2024, 7:00 AM EST - 10 months ago

Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November

Oct 18, 2024, 10:51 AM EDT - 10 months ago

This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

COFS NEON PCT SELF

Sep 17, 2024, 2:35 AM EDT - 1 year ago

Rapport semestriel Pilier 3 - 30 juin 2024

Sep 5, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present at Upcoming Epilepsy Medical Conferences

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Rapport Therapeutics to Present Data for TARPγ8 AMPAR Negative Modulator at IASP 2024 World Congress on Pain

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement

Jun 7, 2024, 11:48 AM EDT - 1 year ago

J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut

JNJ

Jun 6, 2024, 7:57 PM EDT - 1 year ago

J&J-backed Rapport Therapeutics raises $136 mln in US IPO

JNJ

Jun 6, 2024, 6:54 PM EDT - 1 year ago

Rapport Therapeutics Announces Pricing of Initial Public Offering

Jun 3, 2024, 1:14 PM EDT - 1 year ago

J&J-backed Rapport Therapeutics seeks about $637 mln valuation in US IPO

JNJ

May 22, 2024, 4:17 PM EDT - 1 year ago

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

Doozio Aug. 19 at 12:56 AM

Out of 🐑⏰♾️ it’s a $RAPP wen they $ALLY $LE oop on 🐑 during as 🐒🍌🧠⏰♾️ gets its $SWAG

0 · Reply

Doozio Aug. 17 at 10:35 PM

Out of 🐑⏰♾️ it’s a $RAPP with Roger rocking this new Baker Bros pos during 🐒🍌🧠⏰♾️

0 · Reply

perchedcats Aug. 9 at 3:11 PM

$RAPP few follow this… catalyst coming up… i am staying on sidelines feel valuation is a bit high already will wait until readout

0 · Reply

d_risk Aug. 7 at 2:26 PM

0 · Reply

JarvisFlow Aug. 6 at 11:30 AM

HC Wainwright & Co. has adjusted their stance on Rapport Therapeutics ( $RAPP ), setting the rating to Buy with a target price of 31.

0 · Reply

UCF_16 Jul. 24 at 11:36 PM

$FIX $RAPP $SCHL $WLGS Lets go $WLGS - to the moon 🌗 🎆🚀🔥

0 · Reply

Whiskey1679 Jul. 24 at 11:35 PM

Whiskeya Picks out tomorrow approx. 6:20 am PDT! Trending: $SCHL $FIX $RAPP $WLGS $BMIX

0 · Reply

Quantumup Jul. 18 at 12:46 PM

1 · Reply

Quantumup Jul. 16 at 10:02 AM

0 · Reply

oneyedjacks Jul. 10 at 8:04 PM

$RAPP Garbage

0 · Reply

JarvisFlow Jul. 8 at 2:15 PM

JMP Securities has updated their rating for Rapport Therapeutics ( $RAPP ) to Market Outperform with a price target of 28.

0 · Reply

DonCorleone77 Jul. 1 at 10:58 AM

$RAPP Rapport Therapeutics files $400M mixed securities shelf

0 · Reply

bilocelhi Jun. 4 at 2:04 PM

$AGEN and $RAPP my top 2 bios

0 · Reply

QuiverQuant Jun. 2 at 8:07 PM

Rapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical Pipeline Read more on $RAPP: https://www.quiverquant.com/news/Rapport+Therapeutics+Hosts+Inaugural+Investor+and+Analyst+Day+to+Update+on+RAP-219+and+Clinical+Pipeline

0 · Reply

_www_larval_com_ Jun. 2 at 7:53 PM

$ZONE -22%[64%] $NIVF 4%[-12%] $KIDZ 3%[38%] $GPUS 3%[-12%] $RAPP 3%[15%] most notable movement into the final minutes of trading.

0 · Reply

lecorb May. 29 at 12:29 PM

$REVB $NTLA $RAPP Crashed

0 · Reply

mikedumbledar May. 29 at 11:59 AM

$RAPP why down 25%? i dont see any news

0 · Reply

JarvisFlow Apr. 8 at 4:45 PM

JMP Securities has adjusted their stance on Rapport Therapeutics ( $RAPP ), setting the rating to Market Outperform with a target price of 28.

0 · Reply

_www_larval_com_ Apr. 7 at 7:58 PM

$LHSW 6%[12%] $ARTV 4%[40%] $BJDX -3%[112%] $RAPP -3%[7%] most notable movement into the final minutes of trading.

0 · Reply

Josephylor Apr. 4 at 7:46 PM

$RAPP In today's market downturn, savvy investors recognize that opportunities often arise when stocks are undervalued. Nuvve stands out as a compelling investment during these times. Competitive Edge: ✅ Advanced vehicle-to-grid (V2G) technology ✅ Bidirectional Charging: Unlike many competitors, Nuvve enables EVs to return power to the grid, enhancing grid efficiency ✅ AI-Powered Energy Management: Utilizes artificial intelligence to optimize energy flow and stabilize the grid ✅ Revenue Generation for EV Owners: Allows EV owners and fleet operators to earn by selling excess energy back to the grid

0 · Reply

Cutlass Mar. 27 at 7:31 PM

$RAPP Stay away - no pipeline, will need to do an offering too - 📉📋📣👀

0 · Reply

Market Cap	532.51M
Revenue (ttm)	0.00
Net Income (ttm)	-78.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	35,278
Avg Vol	157,100
Day's Range	N/A - N/A
Shares Out	36.50M
Stochastic %K	22%
Beta	0.62
Analysts	Strong Sell
Price Target	$34.20